ArticleOncology letters2014
Effect of CXCL12/CXCR4 on increasing the metastatic potential of non-small cell lung cancer
Article in Oncology letters, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 29 citations in OpenAlex.
- Chemokines as Prognostic Factor in Colorectal Cancer Patients: A Systematic Review and Meta-Analysis.International journal of molecular sciences · 2024Pooled it
- ARID1A: gene, protein, and function in endometrial cancer.Oncogene · 2025Review
- Expression of CX3CL1 in the neoplastic lung tissue of squamous cell lung cancer.Journal of Cancer · 2025Article
- Unraveling the alterations and biomarkers in the tumor microenvironment in lung adenocarcinoma metastases and their indications for therapeutic response and prognosis.Therapeutic advances in medical oncology · 2025Review
- CXCR4-targeted therapy in lung cancer: plerixafor as a promising antimetastatic agent.Frontiers in pharmacology · 2025Review
- CRISPR-mediated reversion of oncogenic KRAS mutation results in increased proliferation and reveals independent roles of Ras and mTORC2 in the migration of A549 lung cancer cells.Molecular biology of the cell · 2023Article
- Ribosome induces transdifferentiation of A549 and H-111-TC cancer cell lines.Biochemistry and biophysics reports · 2021Article
- PD-L1Cancer immunology, immunotherapy : CII · 2021Article
- Hesperidin administration suppresses the proliferation of lung cancer cells by promoting apoptosis via targeting the miR‑132/ZEB2 signalling pathway.International journal of molecular medicine · 2020Article
- Placenta‑derived mesenchymal stem cells ameliorate lipopolysaccharide‑induced inflammation in RAW264.7 cells and acute lung injury in rats.Molecular medicine reports · 2020Article
- Article
- JMJD3 promotes the epithelial-mesenchymal transition and migration of glioma cells via the CXCL12/CXCR4 axis.Oncology letters · 2019Article
- Identification of an Unfavorable Immune Signature in Advanced Lung Tumors from Nrf2-Deficient Mice.Antioxidants & redox signaling · 2018Article
- Stem cell autocrine CXCL12/CXCR4 stimulates invasion and metastasis of esophageal cancer.Oncotarget · 2017Article
- Targeting CXCR4 and FAK reverses doxorubicin resistance and suppresses invasion in non-small cell lung carcinoma.Cellular oncology (Dordrecht, Netherlands) · 2017Article
- Chemokines and their receptors in lung cancer progression and metastasis.Journal of Zhejiang University. Science. B · 2016Review
- Inverse expression of somatostatin and CXCR4 chemokine receptors in gastroenteropancreatic neuroendocrine neoplasms of different malignancy.Oncotarget · 2015Article
- Combination Treatment with All-Trans Retinoic Acid Prevents Cisplatin-Induced Enrichment of CD133+ Tumor-Initiating Cells and Reveals Heterogeneity of Cancer Stem Cell Compartment in Lung Cancer.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2015Article
- Expression of CXCR4 and non-small cell lung cancer prognosis: a meta-analysis.International journal of clinical and experimental medicine · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lung cancer ranks as the most common type of cancer in males worldwide. Although great advances have been achieved in chemotherapy and radiotherapy, the long-term survival rate of lung cancer patients has not improved significantly. Dissemination of lung cancer in the thoracic cavity and metastatic spread to the liver, bone and brain are characteristic of non-small cell lung cancer (NSCLC), constituting the primary source of morbidity and mortality in lung cancer. Increasing evidence also indicates that the CXC chemokine receptor 4 (CXCR4)/chemokine CXC motif ligand 12 (CXCL12) chemokine axis is important for the cell invasion and migration of lung cancer. CXCR4 is a G protein-coupled receptor with a major role in lymphocyte homing. Its ligand, CXCL12, is secreted by target organs and functions as a highly efficient chemotactic factor for T cells, monocytes, pre-B cells, dendritic cells and myeloid bone marrow-derived cells. In the current study, recombinant CXCR4-specific small interfering RNA-pBSilence1.1 plasmids were constructed and transfected into the A549 NSCLC cell line
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.